Search

Displaying results 2241 - 2250 of 8195 in total
  1. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct

  2. Drug

    Valrubicin

    go.drugbank.com/drugs/DB00385
    Approved

    It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.

  3. Drug

    Captopril

    go.drugbank.com/drugs/DB01197
    ApprovedInvestigational

    Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the r...

    Categories: P-glycoprotein inhibitorsSynonyms: D-2-methyl-3-mercaptopropanoyl-L-proline, D-3-mercapto-2-methylpropanoyl-L-proline
  4. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost].

  5. Drug

    Clobazam

    go.drugbank.com/drugs/DB00349
    ApprovedIllicitInvestigational

    [A256968,A256973] Clobazam has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. … [A256958] In 2005, clobazam also received approval from Health Canada as an add-on therapy for generalized tonic-clonic, myoclonic, and focal impaired awareness seizures.[A256978]

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Gadoteridol

    go.drugbank.com/drugs/DB00597
    ApprovedInvestigational

    [A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained

    Synonyms: GD-HP-DO 3A
  7. Drug

    Curcumin

    go.drugbank.com/drugs/DB11672
    ApprovedInvestigational

    Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in [Curcuma xanthorrhiza oil]. … Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and Non Small Cell

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    [A242292] Ligelizumab is currently under investigation for the treatment of chronic spontaneous urticaria (CSU), an autoimmune-driven inflammatory condition. … IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer a greater affinity for free serum IgE and an

  9. Drug

    Doravirine

    go.drugbank.com/drugs/DB12301
    ApprovedInvestigational

    Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Roxatidine acetate

    go.drugbank.com/drugs/DB08806
    Investigational

    Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.